Hyundai Pharmaceutical Co., Ltd. (KOSE:A004310) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 worth of its shares pursuant to a contract with Samsung Securities Co. Ltd. The purpose of the program is to enhance shareholder value and to stabilize stock price.

The program will expire on July 12, 2024. As of July 13, 2023, the company had 5,089,756 shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.